Dr. Vivian A. Fonseca
Assistant Dean for Clinical Research, Chief, Section of Endocrinology, Professor of Medicine
Biography
Vivian A. Fonseca, MD, FRCP, is Professor of Medicine, Assistant Dean for Clinical Research, the Tullis–Tulane Alumni Chair in Diabetes, and chief of the Section of Endocrinology at Tulane University Medical Center in New Orleans, Louisiana. He is a Past President for Science and Medicine of the American Diabetes Association (2012). He has served on the Board of Directors of the American Diabetes Association and the American Association of Clinical Endocrinologists (AACE), and the Board of Trustees of the American College of Endocrinology,and has held a leadership role and served on various committees in several other organizations including the the American Board of Internal Medicine.
He is Editor in Chief of the Journal of Diabetes and its Complications. He was Editor in chief of Diabetes Care from 2007-2011, having formerly been associate editor. He was until 2006 Editor in Chief of the Journal of the Metabolic Syndrome and related disorders. He served on the editorial board of the Journal of Clinical Endocrinology and Metabolism (2003-2006), and is an ad hoc reviewer for several other journals, including New England Journal of Medicine, Lancet, JAMA, Diabetes, etc
Dr. Fonseca is a fellow of the Royal College of Physicians (London), and the American College of Physicians. Dr. Fonseca has served on and been chairman of the clinical practice committee of the American Diabetes Association, the ADA Disaster Task Force, ADA strategic planning committee and the joint ADA/ACC “Make the Link” Program. He has played a significant role in developing guidelines for treating diabetes (ADA and AACE), managing chronic disease and clinical trials after a natural disaster and in drawing attention to the global epidemic of diabetes, particularly in Asia.
The American Diabetes Association awarded him the ADA Banting Medal for Leadership and Service and the Southern Medical Association awarded him the Seale – Harris award. The ADA presents the Vivian Fonseca Award annually for research on Diabetes in Asia. He has received several teaching awards and was elected to the Alpha Omega Alpha Honor Medical Society and has been listed for several years among the Best Doctors in the USA, LA and AR.
Education
Vanderbilt University Medical Center
Johns Hopkins University School of Medicine
Royal College of Physicians
Articles
Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials
2019
Context Variations in the prevalence and aetiology of type 2 diabetes (T2D) across race and ethnicity may affect treatment responses. Semaglutide is a glucagon-like peptide-1 (GLP-1) analog approved for once–weekly, subcutaneous (s.c.) treatment of T2D. Objective To compare semaglutide efficacy and safety in race and ethnicity subgroups across the SUSTAIN trials. Design Post hoc analysis of data from phase 3 randomized SUSTAIN 1–5 and 7 (pooled) and SUSTAIN 6 trials.
Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model
2019
To develop a practical solution for modeling diabetes progression and account for the variations in risks of diabetes complications in different regions of the world, which is critical for model-based evaluations on the value of diabetes intervention across populations from different regions globally.
Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a post hoc analysis of the LixiLan‐O and LixiLan‐L trials
2019
Both fasting (FPG) and postprandial plasma glucose (PPG) contribute to HbA1c levels. We investigated the relationship between achievement of American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) recommended FPG and/or PPG targets and glycaemic efficacy outcomes in two trials.
Media Appearances
New Orleans diabetes patients hold fast against King Cake season
"About 50 percent of people managed to come off of their diabetes medications completely, and stayed off for a year. And they call that remission of diabetes which I think is great," said Dr. Fonseca.
What's a DNA bus looking for in New Orleans? Samples, help building database, better treatment
“NIH conceived this program a few years ago, around the time specifically targeted treatments for cancer (depending upon DNA) were being launched,” said Dr. Vivian Fonseca, chief of endocrinology at Tulane and assistant dean for clinical research.
Stop the Progress of Prediabetes
"In simple terms, there is a gap between what we call diabetes, which is a fasting blood sugar of 126 and above, and normal, which is less than 100 fasting," explains Vivian Fonseca, MD, a professor of medicine and pharmacology and chief of endocrinology at Tulane University Health Sciences Center in New Orleans.
